WINTER BONUS MAGAZINE 2026

ENHANCED QUALITY OF LIFE, ACTIVITY AND WELL-BEING ALL-MONTH RELIEF FROM OA PAIN* MINIMAL GI AND RENAL IMPACT WHEN CHRONIC PAIN IS A PROBLEM, ASK YOUR VET FOR A LONG-TERM SOLUTION CHANGE THE DIRECTION OF OA CARE Image enabled by AI. *After the first dose, onset of efficacy was demonstrated after 7 days. 1 VETERINARY MEDICINE Reference: 1. The Librela South African Approved Professional Information. Solution for Injection for dogs. S4 Librela 5 mg/ml. Reg. No. 22/24.5/02. Each ml contains 5 mg bedinvetmab. S4 Librela 10 mg/ml. Reg. No. 22/24.5/03. Each ml contains 10 mg bedinvetmab. S4 Librela 15 mg/ml. Reg. No. 22/24.5/04. Each ml contains 15 mg bedinvetmab. S4 Librela 20 mg/ml. Reg. No. 22/24.5/05. Each ml contains 20 mg bedinvetmab. S4 Librela 30 mg/ ml. Reg. No. 22/24.5/06. Each ml contains 30 mg bedinvetmab. Full product information available from Zoetis South Africa (Pty) Ltd., Co. Reg. No.: 2012/001825/07, 6th Floor, North Wing, 90 Rivonia Road, Sandton, 2196. PostNet Suite 53, Private Bag 9976, Sandton, 2146, South Africa.Tel.: 0800998969. For full prescribing information refer to the professional information approved by the Medicines Regulatory Authority. www.zoetis.co.za MM-46636